Furthermore, two randomized controlled trial studies conducted in India showed that saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR) α/훾 agonist, lowers postprandial TG levels [40] and improves insulin sensitivity assessed using hyperinsulinemic-euglycemic clamp in patients with T2DM and hypertriglyceridemia [41]. Here, PPARA is linked to type 2 diabetes mellitus.